Pharmaceutical companies are actively exploring new sourcing strategies to stem the continuing decline in R&D productivity. Fragmented outsourcing has not sufficiently addressed this, and leaders are moving toward an integrated sourcing model that blends control of the development pipeline with the economies of scalable outsourcing.
While many pharma companies recognize the potential value of this different outsourcing approach, few are prepared to fully exploit it. This point of view explores how Accenture can help.
It’s an understatement to say that pharma R&D organizations are under pressure to deliver differentiated products while holding spending flat. Over the last 15 years (1997-2012), R&D spend has grown five percent annually while output in terms of new molecular entities approved has dropped by approximately 22 percent. Significant change is required.
While external sourcing has become an increasingly common way to try to manage cost and boost efficiency, results typically vary across different outsourcing models. Fragmented outsourcing with multiple specialty niche providers or study-based CRO programs can be challenging.
However, integrated outsourcing allows companies to realize the benefits of outsourcing while maintaining control of the science.